Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-29T20:00:22.912Z Has data issue: false hasContentIssue false
  • English
  • Français

Recurrent respiratory papillomatosis disease course in immunosuppressed populations

Published online by Cambridge University Press:  25 October 2023

Ericka L Erickson Open the ORCID record for Ericka L Erickson [Opens in a new window] ,
Taylor E Freeman ,
Shuai Sun ,
Brandon Koch ,
David Z Allen ,
Rishabh Sethia ,
Brad deSilva  and
Laura Matrka
Ericka L Erickson*
Affiliation:
Ohio State University College of Medicine, Columbus, OH, USA
Taylor E Freeman
Affiliation:
Ohio State University Wexner Medical Center, Columbus, OH, USA
Shuai Sun
Affiliation:
Ohio State University Department of Public Health, Columbus, OH, USA
Brandon Koch
Affiliation:
Ohio State University Department of Public Health, Columbus, OH, USA
David Z Allen
Affiliation:
University of Texas Health Science Center at Houston, Houston, TX, USA
Rishabh Sethia
Affiliation:
Ohio State University Wexner Medical Center, Columbus, OH, USA
Brad deSilva
Affiliation:
Ohio State University Wexner Medical Center, Columbus, OH, USA
Laura Matrka
Affiliation:
Ohio State University Wexner Medical Center, Columbus, OH, USA
*
Corresponding author: Ericka Erickson; Email: Ericka.erickson@osumc.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Recurrent respiratory papillomatosis is a benign manifestation of human papillomavirus types 6 and 11 in the respiratory tract. Disease is recurrent, and factors predicting these recurrences and severity of disease are incompletely characterised. This retrospective cohort study examined the relationship of immunosuppression with recurrent respiratory papillomatosis morbidity.

Methods

A retrospective cohort of 97 adult patients with recurrent respiratory papillomatosis treated at a tertiary referral centre from 2005 to 2020 was conducted. Measures assessed included inter-surgical interval, Voice Handicap Index (‘VHI-10’) and anatomical Derkay scores.

Results

Bivariate analyses comparing average inter-surgical interval, Voice Handicap Index and Derkay scores in immunosuppressed and healthy patients were insignificant. When controlling for diabetes mellitus and comparing immunosuppressed to healthy patients, inter-surgical interval and Voice Handicap Index change were insignificant (p = 0.458 and p = 0.465, respectively).

Conclusion

Recurrent respiratory papillomatosis morbidity for immunosuppressed patients did not significantly differ from that of immunocompetent patients.

Keywords

Laryngeal diseasesimmunosuppressiondiabetes mellitushuman papillomavirus
Type
Main Article
Information
The Journal of Laryngology & Otology , First View , pp. 1 - 5
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Ericka Erickson takes responsibility for the integrity of the content of the paper

References

Derkay, CS, Bluher, AE. Update on recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2019;52:669–79CrossRefGoogle ScholarPubMed
Katsenos, S, Becker, HD. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol 2011;4:162–71CrossRefGoogle Scholar
Bauman, NM, Smith, RJH. Recurrent respiratory papillomatosis. Pediatr Clin North Am 1996;43:1385–401CrossRefGoogle ScholarPubMed
Karatayli-Ozgursoy, S, Bishop, JA, Hillel, A, Akst, L, Best, SRA. Risk factors for dysplasia in recurrent respiratory papillomatosis in an adult and pediatric population. Ann Otol Rhinol Laryngol 2016;125:235–41CrossRefGoogle Scholar
Zeitels, SM, Barbu, AM, Landau-Zemer, T, Lopez-Guerra, G, Burns, JA, Friedman, AD et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011;120:627–34CrossRefGoogle ScholarPubMed
Taliercio, S, Cespedes, M, Born, H, Ruiz, R, Roof, S, Amin, MR et al. Adult-onset recurrent respiratory papillomatosis: a review of disease pathogenesis and implications for patient counseling. JAMA Otolaryngol Head Neck Surg 2015;141:78–83CrossRefGoogle ScholarPubMed
Ivancic, R, Iqbal, H, deSilva, B, Pan, Q, Matrka, L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018;3:22–34CrossRefGoogle ScholarPubMed
Co, J, Woo, P. Serial office-based intralesional injection of cidofovir in adult-onset recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2004;113:859–62CrossRefGoogle ScholarPubMed
Riss, D, Burian, M, Wolf, A, Kranebitter, V, Kaider, A, Arnoldner, C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck 2015;37:783–7CrossRefGoogle Scholar
Yiu, Y, Fayson, S, Smith, H, Matrka, L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2019;128:309–15CrossRefGoogle ScholarPubMed
San Giorgi, MRM, Aaltonen, L-M, Rihkanen, H, Tjon Pian Gi, REA, van der Laan, BFAM, Hoekstra-Weebers, JEHM et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope 2017;127:1826–31CrossRefGoogle ScholarPubMed
Derkay, CS, Wiatrak, B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008;118:1236–47CrossRefGoogle ScholarPubMed
Lindman, JP, Lewis, LS, Accortt, N, Wiatrak, BJ. Use of the Pediatric Quality Of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005;114:499–503CrossRefGoogle ScholarPubMed
Mauz, PS, Schäfer, FA, Iftner, T, Gonser, P. HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis. BMC Infect Dis 2018;18:343CrossRefGoogle ScholarPubMed
Matsuzaki, H, Makiyama, K, Hirai, R, Suzuki, H, Asai, R, Oshima, T. Multi-year effect of human papillomavirus vaccination on recurrent respiratory papillomatosis. Laryngoscope 2020;130:442–7CrossRefGoogle Scholar
Shehab, N, Sweet, BV, Hogikyan, ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 2005;25:977–89CrossRefGoogle ScholarPubMed
Lee, CJ, Allen, CT, Merati, AL. Prevalence of diabetes mellitus and its impact on disease severity in adult recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2013;149:603–7CrossRefGoogle ScholarPubMed
Akash, MSH, Rehman, K, Fiayyaz, F, Sabir, S, Khurshid, M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol 2020;202:953–65CrossRefGoogle ScholarPubMed
Kupfer, RA, Çadalli Tatar, E, Barry, JO, Allen, CT, Merati, AL. Anatomic Derkay score is associated with voice handicap in laryngeal papillomatosis in adults. Otolaryngol Head Neck Surg 2016;154:689–92CrossRefGoogle ScholarPubMed
Bonagura, VR, Hatam, LJ, Rosenthal, DW, de Voti, JA, Lam, F, Steinberg, BM et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010;118:455–70CrossRefGoogle ScholarPubMed
Alves, C, Casqueiro, J, Casqueiro, J. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012;16(suppl 1):S27–36CrossRefGoogle Scholar
Baltzis, D, Eleftheriadou, I, Veves, A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther 2014;31:817–36CrossRefGoogle ScholarPubMed